Osilodrostat

Grey

Brand Name(s):Isturisa

Indication:Endogenous Cushing’s syndrome

Rationale:5

Considered:Sep-20

Review Date:Sep-25

Comments:
Osilodrostat phosphate is licensed for the treatment of endogenous Cushing’s syndrome in adults; and should be initiated and supervised by physicians experienced in endocrinology with access to facilities for monitoring of cortisol levels.
This drug is not routinely commissioned by NHS England and access should be via IFR